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Objective: Aprotinin is used in cardiac surgery for its anti-inflammatory and hemo-
static benefits. Recent reports describe the neuroprotective effects of other serine
protease inhibitors via reduced excitotoxic cell death, a common pathway causing
cytotoxic edema induced in various neuropathologic conditions. The purpose of
this study was to investigate whether aprotinin directly protects against glutamatergic
excitotoxicity in cell cultures.
Methods: Mixed cortical cultures containing neuronal and glial cells were prepared
from fetal mice at 13 to 15 days’ gestation and plated on a layer of confluent astrocytes
from 1- to 3-day-old postnatal pups. Near-pure neuronal culture containing less than
5% astrocytes was obtained from the same gestational stage and plated in multiwell
vessels previously coated with poly-D-lysine and laminin. Both cultures were used
at 12 to 14 days in vitro. Slowly triggered excitotoxicity was induced at 37C by
24-hour exposure to 12.5 mM N-methyl-D-aspartate or 50 mM kainate. Neuronal
death was quantified by measuring the release of lactate dehydrogenase from
damaged cells into the bathing medium. Data were analyzed by analysis of variance
with post hoc Bonferroni comparisons.
Results: Aprotinin at a clinically relevant concentration of 100 KIU/mL significantly
reduced N-methyl-D-aspartate–induced neuronal death in both pure and mixed
cultures (P , .001). Aprotinin also reduced neuronal death induced by kainate
from 36% to 23% in mixed cortical culture (P 5 .008) and from 40% to 27% in
near-pure culture (P 5 .015), indicating that the neuroprotective effects of aprotinin
are mediated directly through neurons.
Conclusion: Aprotinin provides direct neuroprotection against glutamatergic excito-
toxicity as demonstrated by reduced neuronal death in near-pure neuronal cell culture.
Additional studies are needed to evaluate the potential of aprotinin to reduce neuro-
logic injury in patients at high risk of cerebral injury, including those undergoing
circulatory arrest.
A
protinin is a broad-spectrum serine protease inhibitor with a molecular
weight of 6512 d. It was first introduced into clinical practice for the treat-
ment of pancreatitis. It is widely used in congenital cardiac surgery for its
hemostatic and anti-inflammatory benefits,1-3 although its safety when used in adults
undergoing coronary artery surgery has recently been questioned.4 The hemostatic
effects of aprotinin are mediated by the preservation of platelet function and reduced
fibrinolysis through inhibition of multiple proteases, including plasmin, plasminogen,
and plasminogen activator.5,6 Aprotinin reduces the inflammatory response to cardio-
pulmonary bypass through reduced complement and neutrophil activation.7,8
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We previously studied the neuroprotective potential of
aprotinin using a piglet model of deep hypothermic circula-
tory arrest. Aoki and colleagues9 described accelerated re-
covery of cerebral adenosine triphosphate and intracellular
pH determined by magnetic resonance spectroscopy, and
showed that aprotinin preserved endothelial-mediated vaso-
dilation. Anttila and colleagues10 demonstrated that aprotinin
reduced rolling and adherent leukocytes in the cerebral circu-
lation measured by intravital microscopy and improved neu-
robehavioral outcomes after a prolonged period of deep
hypothermic circulatory arrest or low-flow cardiopulmonary
bypass. We concluded from our 2 previous studies that the
primary neuroprotective effect of aprotinin was accelerated
recovery of the microcirculation.
In addition to microvascular injury, ischemic brain injury
can be mediated through ‘‘excitotoxicity,’’ which causes
excessive calcium influx through N-methyl-D-aspartate
(NMDA), AMPA, and kainate pathways. Nicole and col-
leagues11,12 investigated the mechanism by which ischemic
stroke could sometimes be exacerbated by the thrombolytic
agent tissue plasminogen activator (tPA). They found that
tPA exaggerates NMDA-mediated excitotoxicity and
confirmed that inhibition of tPA by the serine protease inhib-
itor plasminogen activator inhibitor-1 reduces NMDA, but
not kainate-induced excitotoxic neuronal death in a cell cul-
ture model. This work expanded on a previous report from
the same center in which Buisson and colleagues13 reported
that up-regulation of plasminogen activator inhibitor-1 in
astrocytes was neuroprotective against ischemic neuronal
death. tPA is present as an endogenous protease even when
it is not used as an exogenous thrombolytic agent. We
hypothesized that the inhibition of intrinsic tPA by the
broad-spectrum serine protease inhibitor aprotinin would be
neuroprotective. Lebeurrier and colleagues14 demonstrated
that NMDA excitotoxic neuronal injury could also be re-
duced by a newly discovered serine protease inhibitor named
‘‘neuroserpin,’’ suggesting that other mechanisms involving
serine protease inhibition might be neuroprotective.15
The purpose of this study was to investigate whether apro-
tinin has a direct neuroprotective effect against glutamatergic
excitotoxicity using both mixed and near-pure neuronal cell
culture models.
Materials and Methods
Glial Cultures
Glial cell cultures were prepared from 1 to 3-day-old postnatal mice
(Taconic, Rockville, Md), as described by Rose and colleagues.16574 The Journal of Thoracic and Cardiovascular Surgery c MarDissociated cortical cells were plated in multiwell vessels previ-
ously coated with poly-D-lysine (Sigma, St Louis, Mo) using
a plating medium of medium stock (Dulbecco’s Modified Eagle’s
Medium with 25 mmol/L glucose; Sigma) supplemented with
10% horse serum (Gibco, Carlsbad, Calif), 10% fetal bovine serum
(Gibco), and 2 mmol/L glutamine. Cultures were kept at 37C in
a humidified 5% CO2-containing atmosphere until they reached
confluence 7 to 14 days in vitro. Confluent cultures were then
used as a support for mixed cultures.
Mixed Cortical Cultures
Mixed cortical cultures containing both neurons and astrocytes were
prepared from fetal mice at 14 to 15 days gestation.16 Dissociated
cortical cells were plated in 24 wells on a layer of confluent astro-
cytes, using medium stock supplemented with 5% horse serum,
5% fetal bovine serum, and 2 mmol/L glutamine. After 7 days in
vitro, non-neuronal cell division was halted by 2 to 3 days of expo-
sure to 10 mM cytosine arabinoside (Ara-C; Sigma). Subsequent
partial medium replacement was performed twice per week, and
after 12 days in vitro, cultures were shifted to a maintenance medium
identical to the plating medium but lacking serum, because neurons
survive without it. Experiments were performed on cortical cultures
after 13 to 14 days in vitro.
Near-pure Neuronal Cell Cultures
The cultures containing less than 5% astrocytes were prepared as
detailed previously by Rose and colleagues.16 Dissociated cortical
cells in medium stock supplemented with 5% fetal bovine, 5% horse
serum, and 2 mmol/L glutamine were plated in multiwell vessels
that had been coated with poly-D-lysine and laminin (Invitrogen,
Carlsbad, Calif). After 3 days in vitro, non-neuronal cell division
was halted by exposure to 10 mM Ara-C. There was no further
exchange of the media except the addition of Dulbecco’s Modified
Eagle’s Medium for evaporation. After 12 days in vitro, the cultures
did not need the presence of serum to survive. They were shifted to
a maintenance medium identical to the plating medium but lacking
serum. Cultures were used after 13 to 14 days in vitro for excitotoxic
injury.
Excitotoxicity
Slowly triggered excitotoxicity was induced at 37C by 24-hour
exposure to 12.5 mM NMDA (Tocris, Ellisville, Mich) or 50 mM
kainate (Tocris) as an excitotoxin in medium stock supplemented
with 10 mMglycine;17,18 10 mMMK-801 (Tocris) was always added
concurrently with kainate to block secondary NMDA receptor acti-
vation. Aprotinin (Bayer HealthCare Pharmaceuticals, Wayne, NJ)
was co-applied at 3 different concentrations (100, 150, or 200
KIU/mL) with the excitotoxin and left for 24 hours in the bathing
medium. Aprotinin concentrations were determined according to
the current clinical target level of 200 KIU/mL, because aprotinin
inhibits plasmin at the concentration of 50 KIU/mL, kallikrein at
the concentration of 200 KIU/mL, and platelet aggregation at the
concentration of approximately 160 KIU/mL.
Assessment of Neuronal Cell Death
Neuronal death was confirmed by examining cultures under phase-
contrast microscopy and quantified by measurement of lactate
dehydrogenase (LDH) release from damaged cells into the bathing
medium 1 day after the onset of excitotoxin exposure.19 LDH wasch 2008
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Pmeasured by an enzyme-linked immunosorbent assay kit (Promega,
Madison, Wis). The LDH level corresponding to complete neuronal
death (without glial death) was determined in sister cultures exposed
to 100 mM NMDA. Background LDH levels were determined in
sister cultures with sham wash as a control and subtracted from
experimental values to yield the signal specific for experimentally
induced injury.
Statistical Analysis
The primary efficacy outcome measure was the percentage of
neuronal cell death. The results are expressed as mean 6 standard
error. When n5 12 is indicated, this value corresponds to 12 differ-
ent wells from 3 different dissections. Analysis of the data included
factorial analysis of variance with the Bonferroni method to protect
against false-positive results. The Statistical Package for the Social
Sciences was used for statistical analysis (version 15.1, SPSS Inc,
Chicago, Ill). Two-tailed values of P less than .05 were used, with
Bonferroni correction as appropriate.
Results
Sham wash and the addition of aprotinin alone at the concen-
tration of 200 KIU/mL did not influence neuronal cells in
either culture (Figure 1, A and B). Excitotoxicity induced
by exposure of the cultures to 12.5 mM NMDA or 50 mM
kainate for 24 hours resulted in acute swelling of neuronal
cell bodies, followed by widespread necrotic neuronal degen-
eration resulting in disrupted neurons and segmentalized
neuritis (Figure 1, C). When aprotinin was co-applied in
the medium with the excitotoxin, aprotinin preserved neuro-
nal cells, including neuritis (Figure 1, D). Exposure to
12.5 mM NMDA caused approximately 70% neuronal cell
death by LDH assay measuring LDH levels in bathingThe Journal of Thormedium in both cultures. In mixed cultures, the percentage
of neuronal cell death was significantly reduced from
69.3% 6 4.6% to 46.1% 6 4.9% with aprotinin concentra-
tion of 100 KIU/mL, 40.0% 6 4.5% with aprotinin concen-
tration of 150 KIU/mL, and 29.3% 6 2.4% with aprotinin
concentration of 200 KIU/mL (Figure 2, A). In near-pure
cultures, neuronal cell death was reduced from 67.6% 6
4.9% to 44.0% 6 4.9% with aprotinin concentration of
100 KIU/mL, 21.6% 6 3.6% with aprotinin concentration
of 150 KIU/mL, and 17.0% 6 3.8% with aprotinin concen-
tration of 200 KIU/mL. The degree of reduction depended
on the concentration of aprotinin. Aprotinin also reduced
the percentage of neuronal cell death induced by exposure
to 50 mM kainate from 36.0% 6 5.0% to 22.9% 6 2.6% in
mixed cultures and from 40.4% 6 4.0% to 27.5% 6 4.6%
in near-pure cultures (Figure 3, A and B). These results sug-
gest that the effect of aprotinin against excitotoxicity induced
by NMDA or kainate was not mediated through glial cells but
directly through neurons.
Discussion
This study is important because it demonstrates that aprotinin
confers direct neuroprotection against excitotoxic cell death.
The protective effect is mediated through neurons and is
effective against both NMDA and kainate-mediated excito-
toxicity.
What Is Excitotoxicity?
Excitotoxicity is one of several mechanisms whereby neu-
rons can be injured or killed after an ischemic insult. High
levels of the excitatory neurotransmitter glutamate result inFigure 1. A, Sham wash (mixed cortical
cultures). Scale bars5 100 mm. B, Apro-
tinin alone. C, Mixed cortical cultures
were exposed to 12.5 mM NMDA for
24 hours and showed an acute swelling
of neuronal cell bodies followed by
a widespread necrotic neuronal degen-
eration resulting in disrupted neurons
and segmentalized neuritis. D, Aprotinin
at a concentration of 200 KIU/mL was
co-applied in the medium with excito-
toxin. Aprotinin preserved neuronal
cells, including neuritis.acic and Cardiovascular Surgery c Volume 135, Number 3 575
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death induced by an exposure to
12.5 mM NMDA revealed approximately
70% neuronal cell death by LDH assay
measuring LDH levels in bathing me-
dium in both cultures. Aprotinin at the
concentration of 100, 150, and 200 KIU/
mL reduced the percentage of neuronal
cell death significantly from 69.3% 6
4.6% to 46.1% 6 4.9%, 40.0% 6 4.5%,
and 29.3% 6 2.4% in mixed cultures
and from 67.6% 6 4.9% to 44.0% 6
4.9%, 21.6% 6 3.6%, and 17.0% 6 3.8%
in near-pure cultures, respectively (A:
mixed cultures; B: near-pure cultures).
*Significantly different from NMDA
alone by analysis of variance with Bon-
ferroni correction (mean 6 standard
error). NMDA, N-methyl-D-aspartate.overactivation of glutamate receptors, resulting in excessive
influx of calcium into cerebral neurons.17,18 Calcium influx
activates a number of enzymes, including phospholipases,
endonucleases, and proteases (eg, calpain). These enzymes
damage cell structures, such as components of the cytoskel-
eton, cell membrane, and DNA.
Glutamate Receptor Subtypes
The glutamate receptors involved in excitotoxic injury
caused by ischemia are normally responsible for excitatory
synaptic transmissions. There are 3 groups of ionotropic glu-
tamate receptors that principally control ion flux: NMDA,
AMPA, and kainate. NMDA receptors are structurally
distinct from kainate receptors and are named for their spe-
cific response to the nonphysiologic agent NMDA. Kainate
receptors respond specifically to kainic acid, another nonphy-
siologic agent known to trigger seizures. Both groups of
receptors in the physiologic setting participate in gluta-
mate-mediated synaptic transmission. Differences in the
response to the excitotoxins NMDA and kainate in the exper-
imental setting allow a greater understanding of the mecha-
nism of excitotoxic injury and specifically the role of
subgroups of glutamate receptors.
Previous studies of the neuroprotective mechanism of the
serine protease inhibitor plasminogen activator inhibitor-1
against excitotoxic injury suggested that tPA specifically
enhanced NMDA-mediated excitotoxicity but not kainate-
mediated excitotoxic injury.13 On the other hand Tsirka
and colleagues20 reported that tPA is the mediator by which
kainate induces neuronal death caused by intrahippocampal
injection of kainic acid. Intrahippocampal injection of kainic
acid induced a loss of laminin immunoreactivity that pre-576 The Journal of Thoracic and Cardiovascular Surgery c Marceded neuronal death. Laminin cleavage and the neuronal
death subsequent to kainate injection were abolished in
tPA-deficient mice or when kainate was co-injected with
alpha 2-antiplasmin in the hippocampus of wild-type mice.
These results suggest that the cleavage of plasminogen into
plasmin by tPA is a key step in the excitotoxicity cascade
mediated through kainate/glutamate receptors.21
The Role of Glial Cells in Excitotoxic Injury
Glial cells play an important role in plasmin-mediated excito-
toxic injury. It has been suggested that ischemic injury leads
to increased tPA expression and subsequent extracellular
release from injured neurons.22 tPA cleaves plasminogen,
and the resulting plasmin degrades extracellular matrix
molecules. Signaling from the injured neurons causes hyper-
sensitivity to direct attacks by tPA, recruitment and activation
of microglia, subsequent release of microglial neurotoxic
factors, and further degradation of extracellular matrix mole-
cules by other proteases activated by plasmin.23 Glial cells
play an important role in the rescue of neurons from ischemic
injury, for example, by release of neuroserpin.14 The present
study demonstrates that aprotinin reduces excitotoxic brain
injury through a direct neuronal effect and without the sup-
port of glial cells.
Our study has documented that NMDA-mediated excito-
toxic injury and kainate-mediated excitotoxic injury are
reduced by aprotinin. Furthermore, the effect of aprotinin is
not affected by the presence of glial cells. Aprotinin was
equally effective in reducing both NMDA excitotoxic injury
and kainate-induced injury in both near-pure neuronal
cultures and mixed glial and neuronal cultures. This is not
surprising in view of aprotinin’s broad spectrum of action.ch 2008
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PAprotinin Is a Broad-spectrum Protease Inhibitor
Aprotinin belongs to the group of Kunitz protease inhibitors.
It is a naturally occurring broad-spectrum serpin obtained
from bovine lung. Aprotinin inhibits a wide range of serine
proteases with varying efficacy. It inhibits proteases such
as kallikrein, trypsin, and plasmin, and reduces complement
activation. Aprotinin has been reported to inhibit neutrophil
elastase release and superoxide anion formation. Further
studies with other specific protease inhibitors are needed to
elucidate the mechanisms by which aprotinin reduces
NMDA and kainate-mediated excitotoxic injury.
Aprotinin and the Blood-Brain Barrier
A question central to this study is the ease with which apro-
tinin crosses the blood-brain barrier. Although an early report
from Bayer Pharmaceuticals suggested that aprotinin does
not pass through the blood-brain barrier, it has been detected
in cerebrospinal fluid after venous administration.24 Further-
Figure 3. A, Percentage of neuronal cell death induced by an ex-
posure to 50 mM kainate revealed approximately 40% neuronal
cell death. Aprotinin reduced percentage of neuronal cell death
induced by an exposure to 50 mM kainate from 36.0% 6 5.0% to
22.9% 6 2.6% in mixed cultures and from 40.4% 6 4.0% to 27.5%
6 4.6% in near-pure cultures (A: mixed cultures; B: near-pure cul-
tures). *Significantly different from NMDA alone by analysis of
variance with Bonferroni correction (mean 6 standard error).The Journal of Thomore, previous studies have suggested that the blood-brain
barrier is at least partially broken down during cardiopulmo-
nary bypass. For example, Cavaglia and colleagues25
detected fluorescent-labeled albumin leaking from micro-
arteries into the brain during cardiopulmonary bypass.
They demonstrated that normothermic cardiopulmonary by-
pass and low temperature increased this leakage of fluores-
cein isothiocyanate-labeled albumin after a brief exposure
of 15 minutes. Given that the blood-brain barrier is immature
in fetuses and newborns, studies are needed to determine the
blood-brain barrier’s permeability to aprotinin in young indi-
viduals undergoing cardiopulmonary bypass.
Other Ways Aprotinin May Reduce Cerebral Injury
Our own previous studies have focused on the vascular
protective effects of aprotinin in whole animal models of
cardiopulmonary bypass. Direct observation of the cerebral
microcirculation confirmed that aprotinin reduced white
cell activation.10 Kamiya26 reported that venous administra-
tion of aprotinin improves the preservation of cerebral aden-
osine triphosphate and reduces cerebral water content after
ischemia. He concluded that cerebral edema is closely related
to plasma and brain tissue bradykinin levels. Murtomaki and
colleagues27 reported that aprotinin rescues dying neurons
from cell death in the weaver mutated mouse as a result of
the restoration of resting membrane potentials of granule
neurons to near normal and neurite outgrowth to normal.
These results suggest that aprotinin may be neuroprotective
against ischemia by reducing inflammation.
Conclusions
This study provides insight into a possible mechanism
whereby aprotinin may be neuroprotective in the setting of
ischemia.
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Discussion
Dr J. Conte (Baltimore, Md). The purpose of your study was to
investigate whether aprotinin directly protects against glutamatergic578 The Journal of Thoracic and Cardiovascular Surgery c Marexcitotoxic injury. I think as far as your data are concerned, you’ve
shown that very nicely. I think we can believe that.
I have 3 methodological questions, and I’d be remiss if I didn’t
go for the low-hanging fruit on this one as well.
The first has to do with the use of fetal tissue. Now, is there any-
thing particular about fetal tissue in cell culture studies like this that
would make it particularly amenable to the prevention of that type of
injury and does it accurately reflect the type of glutamatergic-
stimulated injury that we would see in adolescents or adults in the
whole animal?
The second has to do with the use of a mechanism of slowly
stimulated or slowly triggered excitotoxicity as your slide nicely
demonstrated. Does that accurately reflect the type of injury we
would see with a short period of negative stimulation, such as
hypothermic circulatory arrest, or in situations where we have
embolic types of ischemic injury? Does that slowly triggered
type of mechanism reflect what we would see in that type of real-
life situation?
The third question has to do with aprotinin. Aprotinin was left in
culture for 24 hours. Does that really reflect the mechanism of action
of aprotinin that we would see clinically? Can we translate aproti-
nin’s benefit in a situation where we’ve left it in culture for 24 hours
to a situation where we would use it in near juxtaposition to when an
injury would occur, either hypothermic circulatory arrest or an
ischemic event?
The low-hanging fruit is obvious. In the United States, the Food
and Drug Administration has come down on aprotinin, and many
surgeons are looking twice at whether they want to risk using apro-
tinin because of the reported adverse events and the flurry of law-
suits. Many offices, including our own, are inundated with calls
from patients asking whether they received aprotinin, a week ago,
a year ago, 5 years ago. We’ve even been contacted by malpractice
lawyers who asked if we used aprotinin in a certain patient. Is it
worth it to use it and would you recommend that on the basis of these
studies or on your previous work? If the answer is no, are there other
serine protease inhibitors that might be able to confer the same
advantages?
Dr Iwata. We used fetal cells in our study because adult cells
cannot be grown in an incubator. Therefore we had to use cortical
cells from fetal mice, because they still have potential for growth.
Your second question was why we used slowly triggered excito-
toxicity. It’s a very good question. However, there would be a techni-
cal problem if we used a higher concentration with brief exposure to
NMDAor kainate.Wewould then need to removeNMDAor kainate
to parallel the clinical setting. This is technically difficult, because if
we expose the cells to the air, those cells are going to die. Neurons
cannot be exposed to air. Complete replacement or partial replace-
ment of the bathing medium to allow a briefer exposure to aprotinin
is also difficult because neurons in culture are very sensitive.
In regard to the advisability of using aprotinin clinically, we
realize that this is controversial for adults. However, the majority
of pediatric centers continue to use aprotinin either routinely or
frequently without observing adverse effects.ch 2008
